Last Updated : December 1, 2023
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort descending |
|---|---|---|---|---|---|---|
| Myrbetriq | Mirabegron | Overactive bladder | Withdrawn | |||
| Invokana | Canagliflozin | Diabetes Mellitus, Type 2 | Withdrawn | |||
| Komboglyze | Saxagliptin + metformin | Diabetes Mellitus, Type 2 | Withdrawn | |||
| Lemtrada | Alemtuzumab | Multiple sclerosis, relapsing-remitting | Withdrawn | |||
| Humira | Adalimumab | ulcerative colitis | Withdrawn | |||
| TBC | Darunavir / cobicistat | HIV infection | Withdrawn | |||
| Picato | Ingenol mebutate | Actinic keratosis | N/A | Complete | ||
| Remsima | Infliximab | Ankylosing spondylitis; arthritis, psoriatic; arthritis, rheumatoid; plaque psoriasis | Withdrawn | |||
| Fampyra | Fampridine | Multiple sclerosis, improve walking disability | Withdrawn | |||
| Trintellix | Vortioxetine | Depression, major depressive disorder | Withdrawn |
Last Updated : December 1, 2023